Heartflow, Inc. Successfully Closes Upsized Initial Public Offering
Heartflow, Inc., recognized for its innovative AI technology in addressing coronary artery disease (CAD), has recently announced a significant milestone with the conclusion of its upsized initial public offering (IPO). The company successfully offered a total of 19,166,667 shares of common stock at a public offering price set at $19 per share. This strategic move included an impressive exercise of an option allowing underwriters to acquire an additional 2,500,000 shares, a testament to the strong demand for Heartflow's shares.
Details of the Offering
The total gross proceeds generated from this offering amounted to approximately $364.2 million prior to accounting for underwriting discounts, commissions, and other costs associated with the offering itself. This amplification of interest in Heartflow's stock speaks volumes about investor confidence in the company's unique position in the healthcare technology sector.
Trading Information
Heartflow's common stock has officially initiated trading on the Nasdaq Global Select Market, designated under the ticker symbol "HTFL." This trading commenced shortly before the announcement was made, marking a significant entry into the public market.
Key Players Involved in the IPO
In bringing this offering to fruition, a collective of reputable investment banks played pivotal roles. J.P. Morgan, Morgan Stanley, and Piper Sandler excelled as joint book-running managers for this significant venture. Additional support was provided by Stifel and Canaccord Genuity, who acted as co-managers, demonstrating a collaborative effort in facilitating this successful IPO.
Regulatory Compliance
The offering was conducted in compliance with regulatory guidelines, with a registration statement related to the shares having been duly filed with and approved by the U.S. Securities and Exchange Commission. Potential investors had access to the offering through a formal prospectus, ensuring transparency and adherence to compliance standards.
About Heartflow, Inc.
Heartflow is at the forefront of transforming coronary care by effectively converting coronary artery disease into a condition that can be screened, diagnosed, and managed efficiently. The company’s flagship product, Heartflow One, stands out as the only comprehensive, non-invasive precision coronary care platform. This remarkable platform offers insights throughout the guideline-directed coronary computed tomography angiography (CCTA) pathway, offering clinicians crucial information on patient conditions.
The AI-driven capabilities of Heartflow's platform encompass various advanced analyses including Roadmap™ Analysis, FFRCT Analysis, and Plaque Analysis. These innovations are not only supported by the latest ACC/AHA Chest Pain Guidelines but also validated through over 600 peer-reviewed studies reinforcing Heartflow’s credibility.
Global Impact
Heartflow has made a considerable impact globally, having assisted clinicians in managing over 400,000 patients around the world. This underscores the company's commitment to improving patient outcomes through cutting-edge technology and comprehensive coronary care solutions.
Media and Investor Contacts
For media inquiries, Elliot Levy is the contact point at Heartflow, reachable via email at elevy@heartflow.com. Meanwhile, investors can direct their queries to Nick Laudico at Heartflow, available at nlaudico@heartflow.com.
Frequently Asked Questions
What is the significance of Heartflow's IPO?
Heartflow's IPO highlights the increasing investor confidence in its innovative approach to coronary care and its potential to enhance patient outcomes.
How much capital did Heartflow raise from this IPO?
Heartflow raised approximately $364.2 million from the IPO before deducting costs and fees.
What is Heartflow One?
Heartflow One is a comprehensive, non-invasive precision coronary care platform that provides essential insights into managing coronary artery disease.
Who managed the IPO for Heartflow?
J.P. Morgan, Morgan Stanley, and Piper Sandler served as the joint book-running managers for Heartflow's IPO.
How can I contact Heartflow for more information?
For media inquiries, contact Elliot Levy at elevy@heartflow.com, and for investor-related questions, reach Nick Laudico at nlaudico@heartflow.com.
